Endpoint

Haematocrit

CAT:outcome/haematocritreported in percent

Method

Packed red cell volume as a fraction of whole blood, by automated haematology analyser (calculated from red cell count and mean corpuscular volume) or by microhaematocrit centrifugation. The method is recorded on the edge; centrifuged values run 1 to 3 percent higher because of trapped plasma.

The method is part of the endpoint identity. Studies measuring the same quantity by a different method are held as separate endpoints.

Notes

Direction is population-bound and is set here for the polycythaemia and hyperviscosity context these papers address; IN ANAEMIA THE SAME NUMBER IMPROVES BY RISING, so an edge without the population recorded has an indeterminate sign. Its near-miss is whole blood viscosity, of which this is the dominant determinant - they move together, so reporting both from one study as independent evidence double-counts a single observation. Tightly coupled as well to blood haemoglobin concentration from the same complete blood count, which is a mass concentration in g/dL and not interchangeable; plasma volume shifts move both with no change in red cell mass.

Findings

1 finding from 1 compound, strongest first.

coenzyme Q10 — no detected effect on
LikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull result
“As shown in Table 2, there were no significant differences in hematological parameters (RBC, hemoglobin, hematocrit, MCV, MCH, MCHC, WBC, lymphocyte, neutrophil, and platelet) between CoQ10 and placebo groups at the end of the study (P > 0.05).”
Quoted verbatim from Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial..
Study

RCT
Participants

52
Duration

10 days
Dose

100 mg three times a day after meals, total 300 mg/day
Population

Adults aged 18-65 with 20-60% total body surface area burns admitted to a burn ICU in Isfahan, Iran, all receiving routine burn care and the unit's standard vitamin, selenium, zinc and B-complex supplementation in both arms; secondary outcome.
Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial.2024PMID:38431600

Method

The method is part of the endpoint identity. Studies measuring the same quantity by a different method are held as separate endpoints.

Notes

Findings

1 finding from 1 compound, strongest first.

coenzyme Q10 — no detected effect on

LikelyFindingNull result

“As shown in Table 2, there were no significant differences in hematological parameters (RBC, hemoglobin, hematocrit, MCV, MCH, MCHC, WBC, lymphocyte, neutrophil, and platelet) between CoQ10 and placebo groups at the end of the study (P > 0.05).”

Study: RCT
Participants: 52
Duration: 10 days
Dose: 100 mg three times a day after meals, total 300 mg/day
Population: Adults aged 18-65 with 20-60% total body surface area burns admitted to a burn ICU in Isfahan, Iran, all receiving routine burn care and the unit's standard vitamin, selenium, zinc and B-complex supplementation in both arms; secondary outcome.

Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial.2024PMID:38431600